- Home
- NGNE vs RM Comparison
NGNE vs RM Comparison
Compare NGNE & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- RM
- Stock Information
- Founded
- NGNE 2003
- RM 1987
- Country
- NGNE United States
- RM United States
- Employees
- NGNE N/A
- RM N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- RM Finance: Consumer Services
- Sector
- NGNE Health Care
- RM Finance
- Exchange
- NGNE Nasdaq
- RM Nasdaq
- Market Cap
- NGNE 325.3M
- RM 414.8M
- IPO Year
- NGNE N/A
- RM 2012
- Fundamental
- Price
- NGNE $18.48
- RM $43.75
- Analyst Decision
- NGNE Strong Buy
- RM Hold
- Analyst Count
- NGNE 7
- RM 2
- Target Price
- NGNE $41.86
- RM $30.00
- AVG Volume (30 Days)
- NGNE 110.1K
- RM 52.0K
- Earning Date
- NGNE 08-11-2025
- RM 07-30-2025
- Dividend Yield
- NGNE N/A
- RM 2.74%
- EPS Growth
- NGNE N/A
- RM 35.30
- EPS
- NGNE N/A
- RM 3.47
- Revenue
- NGNE N/A
- RM $591,436,000.00
- Revenue This Year
- NGNE N/A
- RM $16.20
- Revenue Next Year
- NGNE N/A
- RM $7.43
- P/E Ratio
- NGNE N/A
- RM $12.63
- Revenue Growth
- NGNE N/A
- RM 7.19
- 52 Week Low
- NGNE $6.88
- RM $25.41
- 52 Week High
- NGNE $74.49
- RM $43.91
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- RM 82.31
- Support Level
- NGNE $19.59
- RM $36.88
- Resistance Level
- NGNE $20.46
- RM $42.05
- Average True Range (ATR)
- NGNE 1.23
- RM 1.29
- MACD
- NGNE -0.20
- RM 0.49
- Stochastic Oscillator
- NGNE 13.37
- RM 98.79
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.